TOXICITY INFORMATION ON: AROCLOR 1016

TOXICITY

The rat acute oral LD_{50} of AROCLOR 1016 is 2.3 grams/kilogram. When held in continuous 24-hour contact with rabbit skin, the dermal LD_{50} was estimated to be between 1.58 grams/kilogram and 2.0 grams/kilogram. Thus, AROCLOR 1016 is considered to be slightly toxic by ingestion in single doses and by single dermal applications.

When undiluted AROCLOR 1016 was placed into the conjunctival sac of the rabbit eye, a slight degree of irritation resulted. The average score of the 24-, 48- and 72-hour readings was 5.1 on a scale of 110.0. The irritation in 4 of 6 treated eyes had subsided by 72 hours after dosing. The other two treated eyes had regained a normal appearance by 168 hours after dosing.

A severe degree of irritation resulted when undiluted AROCLOR 1016 was held in continuous 24-hour contact with intact and abraded rabbit skin. The Primary Irritation Index was 5.3 on a scale of 8.0.

HANDLING PRECAUTIONS

Care should be taken to avoid AROCLOR 1016 contact with the skin. In case of skin contact, immediately wash exposed surfaces thoroughly with soap and water. If irritation persists, consult a physician.

In case of eye contact, flush immediately with large volumes of water. If irritation persists, consult a physician.

AROCLOR 1016 has a negligible vapor pressure at room temperature and it is not expected to present a significant vapor inhalation hazard under ambient conditions. However, precautions should be observed to avoid inhalation of increased vapor concentrations which may occur if AROCLOR 1016 is used at elevated temperatures.

ENVIRONMENTAL HAZARDS

During the past several years, evidence has accumulated to indicate that polychlorinated biphenyls are widely dispersed throughout the environment and that they can have adverse ecological and toxicological effects. Extreme care should, therefore, be taken by all users of AROCLOR 1016 to prevent any entry into the environment through spills, leakage, use or disposal.

The above information is based upon studies conducted for Monsanto Company. It is believed to be correct, and it is supplied to others upon the condition that the persons receiving it shall make their own determination of its suitability for their purposes. No warranty is expressed or implied regarding the accuracy of this information or the results to be obtained from its use.

Inquiries regarding this information are to be referred to the Corporate Medical Department, 800 N. Lindbergh, St. Louis, Mo. 63166, (314) 694-1000.